Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

Bortezomib/thalidomide/dexamethasone (VTD) induction therapy followed by autologous stem cell transplantation (ASCT) is one of the standard therapies for newly diagnosed multiple myeloma (NDMM). However, the appropriate depth of response to induction therapy and timing of upfront ASCT are still deba...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yoo Jin, Moon, Joon Ho, Sohn, Sang Kyun, Kim, Seok Jin, Jung, Sung-Hoon, Lee, Je-Jung, Jo, Jae-Cheol, Shin, Ho-Jin, Lee, Won Sik, Lee, Ji Hyun, Bae, Sung Hwa, Kim, Min Kyoung, Lee, Ho Sup, Kim, Kihyun, Min, Chang-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763096/
https://www.ncbi.nlm.nih.gov/pubmed/31358918
http://dx.doi.org/10.1038/s41409-019-0629-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763096/
https://www.ncbi.nlm.nih.gov/pubmed/31358918
http://dx.doi.org/10.1038/s41409-019-0629-7

Ejemplares similares